// App-Quantinova.ai

1546 : Comparative Effectiveness of Secukinumab and Golimumab in Ankylosing Spondylitis: Assessed By Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data

Researchers

Presenter

  • Walter P. Maksymowych

Principal Investigators

  • Ernest Choy

  • Yusuf Yazici

  • Jessica A. Walsh

  • Howard Thom

  • Chrysostomos Kalyvas

  • Todd Fox

  • Kunal Gandhi

  • Steffen Jugl

Medical Centers

  • Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada

  • Section of Rheumatology, Cardiff University, Cardiff, Great Britain

  • School of Medicine, New York University School of Medicine, New York City, NY

  • Division of Hematology, The University of Utah, Salt Lake City, UT

  • School of Social and Community Medicine, University of Bristol, Bristol,United Kingdom

  • Real World Strategy and Analytics, MAPI Group, Houten, Netherlands

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

Locations

  • Canada

  • United States

  • United Kingdom

  • Netherlands

  • Switzerland

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • C reactive protein

Drug/Treatment

  • secukinumab

  • golimumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved